Genor Biopharma Holdings (HKSE:06998) Scaled Net Operating Assets : 0.03 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genor Biopharma Holdings's operating assets for the quarter that ended in Jun. 2024 was HK$266.72 Mil. Genor Biopharma Holdings's operating liabilities for the quarter that ended in Jun. 2024 was HK$223.74 Mil. Genor Biopharma Holdings's Total Assets for the quarter that ended in Dec. 2023 was HK$1,582.56 Mil. Therefore, Genor Biopharma Holdings's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.03.

Genor Biopharma Holdings Scaled Net Operating Assets Historical Data

The historical data trend for Genor Biopharma Holdings's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Scaled Net Operating Assets Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.01

0.49

0.10

0.08

0.02

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Scaled Net Operating Assets	Get a 7-Day Free Trial						0.11	0.10	0.11	0.02	0.03

Competitive Comparison of Genor Biopharma Holdings's Scaled Net Operating Assets

For the Biotechnology subindustry, Genor Biopharma Holdings's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Scaled Net Operating Assets falls into.

Save Embed

;

Save Embed

;

Genor Biopharma Holdings Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genor Biopharma Holdings's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(307.785	-	272.375)	/	2361.953
=	0.01

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1582.564	-	1274.779
=	307.785

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	280.201	-	4.292	-	3.534
=	272.375

Genor Biopharma Holdings's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Jun. 2024 )
=	(Operating Assets (Q: Jun. 2024 )	-	Operating Liabilities (Q: Jun. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(266.718	-	223.739)	/	1582.564
=	0.03

where

	Operating Assets		(Q: Jun. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1371.862	-	1105.144
=	266.718

	Operating Liabilities		(Q: Jun. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	227.128	-	2.191	-	1.198
=	223.739

Genor Biopharma Holdings Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

67N:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Forebright New Opportunities Fund, L.p.	2101 Beneficial owner
Forbright Global Limited	2201 Interest of corporation controlled by you
Fnof Gp Limited	2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh	2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd.	2101 Beneficial owner
Hsg Holding Limited	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p.	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p.	2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital I, L.p.	2101 Beneficial owner
Ni Xin	2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines